Autolus Therapeutics (NASDAQ:AUTL) Sees Strong Trading Volume – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL) shares saw strong trading volume on Thursday . 5,096,923 shares traded hands during trading, an increase of 278% from the previous session’s volume of 1,349,308 shares.The stock last traded at $3.58 and had previously closed at $4.00.

Autolus Therapeutics Price Performance

The firm has a market capitalization of $888.75 million, a PE ratio of -2.94 and a beta of 2.04. The firm’s fifty day moving average price is $4.04 and its 200 day moving average price is $4.07. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities analysts forecast that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Renaissance Technologies LLC raised its holdings in Autolus Therapeutics by 253.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after purchasing an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. Millennium Management LLC raised its stake in shares of Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after buying an additional 111,131 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after acquiring an additional 925,000 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.